If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
=== Role in Major Depression Disorder === The cGMP signaling pathway plays a role in the regulation of neuroplasticity, an area of interest in understanding the pathophysiology of major depressive disorder (MDD). The cGMP signaling pathway in the brain operates as a second messenger system, amplifying neurotransmitter signals, influencing gene expression and neuronal function. Within neurons, cGMP levels are modulated by guanylate cyclase enzymes, which synthesize cGMP, and by PDEs, which degrade cGMP. Enhancing cGMP levels, either by stimulating guanylate cyclase or inhibiting PDEs, promotes neurogenesis and synaptic plasticity, particularly in brain regions implicated in MDD, such as the hippocampus and prefrontal cortex. Animal studies also demonstrate that chronic antidepressant treatment can elevate cGMP levels in these areas. Genetic research has further highlighted specific polymorphisms in PDE genes associated with MDD susceptibility and treatment response.
== Etymology == The town's English name, Holyhead, has existed since at least the 14th century. As is the case with many coastal parts of Wales, the name in English is significantly different from its name in Welsh. It refers to the holiness of the locality and has taken the forms Haliheved, Holiheved, Le Holyhede and Holy Head in the past. The Welsh name, Caergybi, derives from the roman fortification around which the town has developed (Caer in Welsh) and Cybi, the name of a sixth-century saint who is believed to have founded a monastery on the site, alongside the local church. The locality was known by such names as Karkeby (1225), Castro Kyby (1291), and Kaer Gybi (1566). Prior to the influence of the fort on the name, the hamlets which came before it were likely known as Llan y Gwyddel ('church/parish of the Irish') and Eglwys y Beddi ('church of the graves').
Fentanyl was followed by sufentanil (1974), alfentanil (1976), carfentanil (1976), and lofentanil (1980). Janssen and his team also developed etomidate (1964), a potent intravenous anesthetic induction agent. The concept of using a fiberoptic endoscope for tracheal intubation was introduced by Peter Murphy, an English anesthetist, in 1967. By the mid-1980s, the flexible fiberoptic bronchoscope had become an indispensable instrument within the pulmonology and anesthesia communities.
The C-terminal precursor DCD-1L is a 48 residue peptide that shows partial helicity in solution, as evidenced by the determination of its solution structure by NMR and CD-spectroscopy. The full length precursor is processed by undetermined proteases present in human sweat, to form several shorter peptides that show variable antimicrobial activity, named according to their C-terminal triplet of amino acids and their residue length. One such active peptide is SSL25, which shows a 2-fold increase in activity against E. coli compared to DCD-1L.
Sources: en.wikipedia.org
==== Erect ==== Scientific studies have been performed on the erect length of the adult penis. Studies that have relied on self-measurement, including from Internet surveys, consistently reported a higher average length than those that used medical or scientific methods to obtain measurements.
== Mechanism == The interfacing mechanism is contained inside a common EI source, like that found in any GC-MS system. The liquid phase from a nano HPLC column is admitted from the capillary column port, where the connection tubing and the nebulizer are first introduced and sealed to prevent vacuum loss. The mechanism is based on the formation of an aerosol in high-vacuum conditions, followed by a quick droplet desolvation and final vaporization of the solute prior to the ionization. The completion of the process is quick and complete and reduces chances of thermal decomposition as reported in the Figure, where a scheme of the interface is shown. The core of the interface is represented by the micro-nebulizer. The nebulizer tip protrudes into the ion source so that the spray expansion is completely contained inside the ion volume. The eluate emerges as liquid phase at a flow rate of 300-500 nL/min, and any premature in-tube solvent evaporation is prevented by a convenient thermal insulation of the nebulizer and the connecting tubing from the surrounding source heat. The high temperature of the ion source, between 300 and 400°C, has a double function: to compensate for the latent heat of vaporization during the droplet desolvation, and to convert the solute into the gas phase. If all components of this simple interface are correctly placed and sized, then each substance separated by the nano-column is smoothly converted into the gas phase, the peak profile is nicely reproduced, and high quality mass spectra are generated.
The odontoblast-like cell is a mineralized structure formed by a new population of pulp-derived cells that can be expressed as Toll-like receptors. They are responsible for the upregulation of innate immunity effectors, including antimicrobial agents and chemokines. One important antimicrobial agent produced by odontoblasts is beta-defensins (BDs). BDs kill microorganisms by forming micropores that destroy membrane integrity and cause leakage of the cell content. Another is nitric oxide (NO), a highly diffusible free radical that stimulates chemokine production to attract immune cells to the affected areas and neutralize bacterial by-products in pulp cells in vitro.
=== Spark Therapeutics === From 2014 to 2020, High was the co-founder, President, Chief Scientific Officer/Head of R&D and a Member of the Board of Directors of Spark Therapeutics, a fully integrated, commercial gene therapy company in Philadelphia. While at Spark Therapeutics, Dr. High led the team that obtained the first FDA approval of an AAV therapeutic (Voretigene neparvovec for the treatment of an inherited disorder causing blindness) in December 2017 and led the teams that obtained Breakthrough Therapy designation and FDA approval for Fidanacogene elaparvovec to treat Hemophilia B and Breakthrough Therapy designation for Dirloctogene samoparvovec to treat Hemophilia A. Spark Therapeutics was bought by Swiss pharma company Roche in December 2019 for $4.3 billion. In February 2020, High stepped down from her position at the company.
=== Enzymatic biotinylation === In contrast to chemical biotinylation methods, enzymatic biotinylation allows biotin to be linked at exactly one residue present in the protein. This biotinylation reaction can also go to completion, meaning that the product is generated with high uniformity and can be linked to streptavidin in a defined orientation e.g. for MHC multimers. Enzymatic biotinylation is most often carried out by E. coli biotin holoenzyme synthetase, also known as biotin ligase (BirA, P06709). The most common way of targeting a protein of interest is by fusing the protein at its N-terminus, C-terminus or at an internal loop to a 15 amino acid peptide (GLNDIFEAQKIEWHE), termed AviTag or Acceptor Peptide (AP). Once tagged, the protein is then incubated with BirA allowing biotinylation to take place in the presence of biotin and ATP. Enzymatic biotinylation can be carried out in vitro but BirA also reacts specifically with its target peptide inside mammalian and bacterial cells and at the cell surface, while other cellular proteins are not modified. Enzymatic biotinylation can also take place in vivo typically through the co-expression of an Avitag tagged protein and BirA. The natural substrate of BirA is the biotin carboxyl carrier protein (BCCP). Before smaller tags were discovered, a protein needed to be fused to the entire BCCP to be targeted. A protein fused by BCCP can be recognized by biotin molecules in vivo and attach to it. A few other small tags have been used before AviTag, but AviTag is the most efficient so far.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.